References
- Barnes NC, Piper PJ, Costell JF. Comparative effects of inhaled leukotriene C4, leukotriene D4 and histamine in normal subjects. Thorax 1984;39:500-4
- Lewis RA. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 1990;323:645-55
- Wenzel SE. The role of leukotrienes in asthma. Prostaglandins Leukot Essent Fatty Acids 2003;69:145-55
- Peters-Golden M, Henderson WR. Leukotrienes. N Engl J Med 2007;357:1841-54
- Dworski R, Fitzgerald GA, Oates JA, et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-9
- Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997;156:737-43
- Vachier I, Bonnans C, Chavis C, et al. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 2005;115:55-60
- Laviolette M, Malmstrom K, Lu S, et al. Montelukast/Beclomethasone Additivity Group. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999;160:1862-8
- Virchow JC Jr, Prasse A, Naya I, et al. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000;162:578-85
- Vaquerizo MJ, Casan P, Castillo J, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58:204-10
- Dupont L, Potvin E, Korn D, et al. Improving asthma control in patients suboptimally controlled on inhaled steroids and long acting beta-2-agonists: addition of montelukast in an open-label pilot study. Curr Med Res Opin 2005;21:863-9
- Keith PK, Koch C, Djandji M, et al. Montelukast as add-on therapy with inhaled corticosteroids or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial). Can Respir J 2009;16(Suppl A):17-24A
- Korn D, Van den Brande P, Potvin E, et al. Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. Curr Med Res Opin 2009;25:489-97
- Gelb AF, Taylor CF, Simmons M, et al. Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate–severe persistent adult asthmatics on fluticasone 250 mg/salmeterol 50 mg. Pulm Pharmacol Therapeut 2009;22:516-21
- Lorrain DS, Bain G, Correa LD, et al. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. Eur J Pharmacol 2010;640:211-18
- Bain G, King C, Schaab K, et al. Pharmacodynamics, pharmacokinetics, and safety of GSK2190915, a potent, novel 5-lipoxygenase-activating protein inhibitor. Br J Clin Pharm 2013;75:779-90
- Follows RM, Snowise NG, Ho SY, et al. Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study. Respir Res 2013;14:54
- Wasfi YS, Villarán C, de Tilleghem Cle B, et al. The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma. Respir Med 2012;106:34-46
- Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-66
- Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010;362:975-85
- Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007;61:663-76